EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases-MedSci.cn

EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases

Jiang, T; Chu, Q; Wang, HJ; Zhou, F; Gao, GH; Chen, XX; Li, XF; Zhao, C; Xu, QH; Li, W; Wu, FY; Xiong, AW; Zhao, J; Xu, YP; Su, CX; Ren, SX; Zhou, CC; Hirsch, FR

Su, CX; Ren, SX; Zhou, CC (reprint author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, 507 Zheng Min Rd, Shanghai 200433, Peoples R China.; Su, CX; Ren, SX; Zhou, CC (reprint author), Tongji Univ, Sch Med, Thorac Canc Inst, 507 Zheng Min Rd

Abstract

To investigate whether addition of local therapy to EGFR-TKIs could provide survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with o......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases

科室

工具

服务